Physician profile
David S Dimarco
NPI 1174540751
$7,330.21
in general payments reported to CMS, 2019-2025
17 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,087 · 2020: $3.82 · 2022: $99.99 · 2023: $159 · 2024: $587 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035 · Education: $94.99 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.39 |
| Education | $94.99 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,348.59 | 2019-2024 | |
| Urogpo LLC | $2,058.89 | 2019 | |
| Telix Pharmaceuticals | $205.40 | 2025 | Illuccix |
| Astellas Pharma US INC | $194.98 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $156.76 | 2025 | Provenge |
| Ferring Pharmaceuticals INC. | $129.64 | 2019 | |
| Janssen Biotech, INC. | $68.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $63.07 | 2023-2025 | Lynparza |
| Sumitomo Pharma America, INC. | $31.69 | 2023 | Gemtesa |
| Amgen INC. | $21.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Endo Pharmaceuticals INC. | $14.29 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.98 | 2019 | |
| Travere Therapeutics, INC. | $3.82 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dimarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.